Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Endocrine Journal

Volumn 58, Issue 6, 2011, Pages 425432-

  Fujitaka, Keisuke ^a   Otani, Hajime ^a   Jo, Fusakazu ^a   Jo, Hiromi ^a   Nomura, Emiko ^a   Iwasaki, Masayoshi ^a   Nishikawa, Mitsushige ^a   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Metabolic syndrome; Pioglitazone; Type 2 diabetes mellitus; Voglibose

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL; VOGLIBOSE;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG WITHDRAWAL; EARLY INTERVENTION; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 79960071614     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.k10e-327     Document Type: Article

References (36)

1. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54-59.
2. Alba AC, Delgado DH (2009) Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? Expert Rev Cardiovasc Ther 7: 147-157.
3. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113: e873-923.
4. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM (2005) Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 336: 747- 753.
5. Sharma AM, Staels B (2007) Review: Peroxisome proliferator- activated receptor gamma and adipose tissue-- understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92: 386-395.
6. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55: 249-259.
7. Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL (2009) Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. Diab Vasc Dis Res 6: 32-37.
8. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373: 1607-1614.
9. (2005) [Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nippon Naika Gakkai Zasshi 94: 794-809 (In Japanese).
10. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010). Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Sos 53: 450-467 (In Japanese)
11. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53: 1621-1629.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
14. Yamagishi S, Nakamura K, Takeuchi M (2005) Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome. Med Hypotheses 65: 152-154.
15. Kobatake T, Matsuzawa Y, Tokunaga K, Fujioka S, Kawamoto T, Keno Y, Inui Y, Odaka H, Matsuo T, Tarui S (1989) Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats. Int J Obes 13: 147-154.
16. Campbell IW (2005) The Clinical Significance of PPAR Gamma Agonism. Curr Mol Med 5: 349-363.
17. Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26: 3148-3152.
18. Aso Y, Hara K, Ozeki N, Yatsuka C, Nakano T, Matsumoto S, Suetsugu M, Nakamachi T, Takebayashi K, Haruki K, Inukai T (2009) Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 85: 147-152.
19. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.
20. Berg AH, Scherer PE (2005) Adipose tissue, inflamma tion, and cardiovascular disease. Circ Res 96:939-949.
21. Yeh ET (2005) High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol 28: 408-412.
22. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP (2008) Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 200: 1-12.
23. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P (2004) New risk factors for atherosclerosis and patient risk assessment. Circulation 109: III15-19.
24. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
25. Goldberg RB (2007) The new clinical trials with thiazolidinediones-- DREAM, ADOPT, and CHICAGO: promises fulfilled? Curr Opin Lipidol 18: 435-442.
26. Nawrocki AR, Hofmann SM, Teupser D, Basford JE, Durand JL, Jelicks LA, Woo CW, Kuriakose G, Factor SM, Tanowitz HB, Hui DY, Tabas I, Scherer PE (2010) Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 30: 1159-1165.
27. Leonhardt W, Pfutzner A, Muller J, Pietzsch J, Forst T, Karagiannis E, Lubben G, Hanefeld M (2008) Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis 201: 155-162.
28. Das M, Gabriely I, Barzilai N (2004) Caloric restriction, body fat and ageing in experimental models. Obes Rev 5: 13-19.
29. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF (2004) A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 117: 398-405.
30. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288: H2031-2041.
31. Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16.
32. Yokoyama H, Kannno S, Ishimura I, Node K (2007) Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism 56: 1458-1463.
33. Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R (2008) Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 55: 549-556.
34. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, Ogawa Y (2006) An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 55: 786- 793.
35. Kavanagh K, Brown KK, Berquist ML, Zhang L, Wagner JD (2010) Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. Metabolism 59: 914-920.
36. Zanchi A, Maillard M, Jornayvaz FR, Vinciguerra M, Deleaval P, Nussberger J, Burnier M, Pechere-Bertschi A (2010) Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia 53: 1568-1575.